Sign in to tag this notice and share notes on it with your team.
Winston AI writes a plain-English brief of every opportunity — what the buyer wants, and what affects whether to bid. It's free in every Scout workspace. Sign in to see it.
The service is to review those prescribed edoxaban in primary care with a view to changing them to a more cost effective alternative.
| Lot | Title | Value |
|---|---|---|
| 1 | Edoxaban Review Service is a service that requires a clinical review of all patients prescribed edoxaban for atrial fibrillation registered with GPs in BCUHB to assess if they are suitable for a more cost effective alternative and then change those that are. Part 1 - Edoxaban Patient Review Clinical review of the records of patients prescribed edoxaban. Anyone not deemed suitable for the switch must be evidenced in the records, consider using the phrase Edoxaban switch not clinically appropriateEdoxaban Review Service is a service that requires a clinical review of all patients prescribed edoxaban for atrial fibrillation registered with GPs in BCUHB to assess if they are suitable for a more cost effective alternative and then change those that are. Part 1 - Edoxaban Patient Review Clinical review of the records of patients prescribed edoxaban. Anyone not deemed suitable for the switch must be evidenced in the records, consider using the phrase Edoxaban switch not clinically appropriate (no code) or, Edoxaban contraindicated (SNOMED CT:2949391000000118) or, Adverse reaction to edoxaban (SNOMED CT:1957181000006103). Those deemed suitable for a switch proceed to a consultation with the patient or their representative. Consultations to switch edoxaban to generic apixaban or generic rivaroxaban can be done via telephone, virtually or face-to-face. This must be documented in the notes, consider using the phrase Edoxaban switch clinically appropriate (no code) or, Edoxaban declined (SNOMED CT:1443911000000106) Part 2 - Edoxaban Patient Review that results in a switch to generic apixaban or generic rivaroxaban If clinically appropriate and the patient agrees to the switch to either generic rivaroxaban or generic apixaban; prescribe as indicated. This is a new service and will run from 1st August 2026 until 31st January 2027. This is a Provider Selection Regime Wales (PSR Wales) intention to award notice. The awarding of this contract is subject to the Health Services (Provider Selection Regime) (Wales) Regulations 2025. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015/Procurement Act 2023 do not apply to this award. |
| Title | Supplier | Value | Awarded |
|---|---|---|---|
| Award 070129-2026-BCU-MSP02-Edoxaban-W91028-1 | Park House Surgery W91028 | — | — |
| — |